Hutchmed China Limited Adr (HCM)

概要ニュース株価時系列オプションチェーンディスカッション予測

Relative Volume:

ネットキャッシュフロー:

Hutchmed China Limited Adr Stock (HCM) Company Profile

Hutchmed China Limited Adr

Healthcare (1069)

HCM's Discussions on Twitter

Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
HCM Hutchmed China Limited Adr	12.82	2.23B	549.97M	458.86M	-89.06M	2.6236
TAK Takeda Pharmaceutical Co Adr	18.26	58.31B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	37.09	43.22B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.19	40.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.97	30.15B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	497.11	21.32B	3.17B	1.29B	1.01B	27.09

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2025-09-22	ダウングレード	Morgan Stanley	Equal-Weight → Underweight
2025-05-13	ダウングレード	HSBC Securities	Buy → Hold
2023-11-24	アップグレード	Deutsche Bank	Hold → Buy
2022-05-04	ダウングレード	Deutsche Bank	Buy → Hold
2021-09-22	ダウングレード	Goldman	Buy → Neutral
2021-08-03	開始されました	Jefferies	Buy
2020-10-02	開始されました	Deutsche Bank	Buy
2020-03-13	開始されました	Cantor Fitzgerald	Overweight
2020-02-20	開始されました	Goldman	Buy
2019-11-19	開始されました	CLSA	Buy
2019-10-23	繰り返されました	BofA/Merrill	Buy
2019-07-05	開始されました	Macquarie	Outperform

Hutchmed China Limited Adr (HCM) 最新ニュース

Hutchmed China Limited Adr (HCM) 財務データ

Hutchmed China Limited Adr (HCM)

Hutchmed China Limited Adr Stock (HCM) Company Profile

Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Hutchmed China Limited Adr (HCM) 最新ニュース

symbol__ Stock Quote Price and Forecast - CNN

Trinity Delta Lighthouse: HUTCHMED - Vox Markets

Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research

China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance

HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat

Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com

Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com

GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan

HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire

Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research

HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research

HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat

HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media

HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com

HUTCHMED (China) LimitedADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat

HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat

HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView

HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan

HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan

ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView

HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn

HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com

REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - finance.yahoo.com

A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView

HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat

Sea Limited Sponsored ADR (SE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance

Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView

HCM Stock Price, Quote & Chart - ChartMill

Sea Limited Sponsored ADR (SE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan

HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire

Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView

HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan

HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire

HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView

H7T1 Forecast — Price Target — Prediction for 2027 - TradingView

0J7G Forecast — Price Target — Prediction for 2027 - TradingView

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LSX:A2AF74) - TradingView

HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (NASDAQ:HCM) - TradingView

Pivotal fanregratinib ICC data and China NDA review for HUTCHMED (NASDAQ: HCM) - Stock Titan

RCSHutchmed China LtdHUTCHMED Highlights Phase II Data at ESMO - TradingView

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib - GlobeNewswire

Hutchmed China Limited Adr (HCM) 財務データ

収益

当期純利益

現金流量

EPS

HCMに似た銘柄